Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has announced the offering of 1,468,000 Common Shares and pre-funded warrants to purchase up to 32,000 Common Shares. The offering is made pursuant to a prospectus supplement and the accompanying prospectus filed under Rule 424(b)(5) with a registration number of 333-275991. The Common Shares are being offered at a price of $1.60 per share, while the pre-funded warrants are offered at $1.5999, with each warrant exercisable for one Common Share at an exercise price of $0.0001. The warrants are immediately exercisable and will not expire until fully exercised. Clearmind's Common Shares are traded on the Nasdaq Capital Market under the symbol 'CMND,' with the last reported sale price on Nasdaq...Show More

Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has announced the offering of 1,468,000 Common Shares and pre-funded warrants to purchase up to 32,000 Common Shares. The offering is made pursuant to a prospectus supplement and the accompanying prospectus filed under Rule 424(b)(5) with a registration number of 333-275991. The Common Shares are being offered at a price of $1.60 per share, while the pre-funded warrants are offered at $1.5999, with each warrant exercisable for one Common Share at an exercise price of $0.0001. The warrants are immediately exercisable and will not expire until fully exercised. Clearmind's Common Shares are traded on the Nasdaq Capital Market under the symbol 'CMND,' with the last reported sale price on Nasdaq being $2.93 as of January 10, 2024. The company has also listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange under the same symbol. The offering aims to raise capital for general corporate purposes, which may include research and development, clinical testing of product candidates, working capital, and potential future acquisitions. The securities offering is expected to close on or about January 16, 2024, subject to customary closing conditions.